Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CTH-401
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $15.0 million
Deal Type : Private Placement
Cartherics Raises $15M To Advance Cell Therapy Programs
Details : The funding will support the clinical trial for CTH-401, the Company’s lead cell therapy and the only natural killer (NK) cell product currently under development for ovarian cancer.
Product Name : CTH-401
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 30, 2024
Lead Product(s) : CTH-401
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $15.0 million
Deal Type : Private Placement
Lead Product(s) : CTH-004
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Shunxi Holding Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cartherics Grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China
Details : The agreement provides Shunxi a licence to develop, manufacture and commercialise CTH-004, for the treatment of multiple solid tumours including ovarian cancer in Greater China, as well as an option to negotiate rights to other CAR-T products that incorp...
Product Name : CTH-004
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 28, 2023
Lead Product(s) : CTH-004
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Shunxi Holding Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement